Two crystal structures reveal design for repurposing the C-Ala domain of human AlaRS.

Proc Natl Acad Sci U S A

The Scripps Laboratories for tRNA Synthetase Research, The Scripps Research Institute, La Jolla, CA 92037;

Published: December 2016

The 20 aminoacyl tRNA synthetases (aaRSs) couple each amino acid to their cognate tRNAs. During evolution, 19 aaRSs expanded by acquiring novel noncatalytic appended domains, which are absent from bacteria and many lower eukaryotes but confer extracellular and nuclear functions in higher organisms. AlaRS is the single exception, with an appended C-terminal domain (C-Ala) that is conserved from prokaryotes to humans but with a wide sequence divergence. In human cells, C-Ala is also a splice variant of AlaRS. Crystal structures of two forms of human C-Ala, and small-angle X-ray scattering of AlaRS, showed that the large sequence divergence of human C-Ala reshaped C-Ala in a way that changed the global architecture of AlaRS. This reshaping removes the role of C-Ala in prokaryotes for docking tRNA and instead repurposes it to form a dimer interface presenting a DNA-binding groove. This groove cannot form with the bacterial ortholog. Direct DNA binding by human C-Ala, but not by bacterial C-Ala, was demonstrated. Thus, instead of acquiring a novel appended domain like other human aaRSs, which engendered novel functions, a new AlaRS architecture was created by diversifying a preexisting appended domain.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167178PMC
http://dx.doi.org/10.1073/pnas.1617316113DOI Listing

Publication Analysis

Top Keywords

human c-ala
12
c-ala
9
crystal structures
8
domain human
8
acquiring novel
8
sequence divergence
8
divergence human
8
appended domain
8
human
6
alars
6

Similar Publications

Objective: To evaluate the efficacy of CO2 fractional laser and microneedling pretreatment combined with ALA-PDT for moderate-to-severe acne, aiming to optimize clinical treatment.

Methods: Patients were randomly divided into three groups: Group A (CO2 fractional laser + ALA-PDT), Group B (microneedling + ALA-PDT), and Group C (ALA-PDT). Each group underwent photodynamic therapy once a week for 3 weeks.

View Article and Find Full Text PDF

Background: There is a need to better understand the relationship between the diet, the gut microbiota and mental health. Metabolites produced when the human gut microbiota metabolize amino acids may enter the bloodstream and have systemic effects. We hypothesize that fermentation of amino acids by a resistant protein-primed gut microbiota could yield potentially toxic metabolites and disturb the availability of neurotransmitter precursors to the brain.

View Article and Find Full Text PDF

Through dominant mutations, aminoacyl-tRNA synthetases constitute the largest protein family linked to Charcot-Marie-Tooth disease (CMT). An example is CMT subtype 2N (CMT2N), caused by individual mutations spread out in AlaRS, including three in the aminoacylation domain, thereby suggesting a role for a tRNA-charging defect. However, here we found that two are aminoacylation defective but that the most widely distributed R329H is normal as a purified protein in vitro and in unfractionated patient cell samples.

View Article and Find Full Text PDF

The uniqueness of AlaRS and its human disease connections.

RNA Biol

November 2021

School of Public Health (Shenzhen), Sun Yat-sen University, Guangdong, China.

Among the 20 cytoplasmic aminoacyl-tRNA synthetases (aaRSs), alanyl-tRNA synthetase (AlaRS) has unique features. AlaRS is the only aaRS that exclusively recognizes a single G3:U70 wobble base pair in the acceptor stem of tRNA, which serves as the identity element for both the synthetic and the proofreading activities of the synthetase. The recognition is relaxed during evolution and eukaryotic AlaRS can mis-aminoacylate noncognate tRNAs with a G4:U69 base pair seemingly as a deliberate gain of function for unknown reasons.

View Article and Find Full Text PDF
Article Synopsis
  • Glutaminase inhibitors, like CB-839, block the conversion of glutamine to glutamate, which is crucial for amino acid synthesis and could impact cancer cell growth, particularly in triple-negative breast cancer (TNBC) and other malignancies.
  • The study investigated how two breast cancer models, one luminal-like (MAS98.06) and one basal-like (MAS98.12), respond to CB-839 treatment, focusing on tumor growth and the metabolic effects of glutamine utilization.
  • Results indicated that CB-839 effectively inhibited tumor growth in the MAS98.06 model but not in MAS98.12, and this was linked to differences in how the tumors metabolized glutamine, with MAS98.06 using it more
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!